Cotellic (cobimetinib) Patient Assistance Program
Don’t let the high cost of brand MEK inhibitor disrupt your BRAF V600-mutated melanoma combination treatment. We help eligible patients access Cotellic (cobimetinib tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Cotellic (cobimetinib) is FDA-approved in combination with vemurafenib for adults with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and in combination with atezolizumab plus vemurafenib for BRAF V600 mutation-positive advanced melanoma (IMspire150 — historical first-line). Oral MEK1/2 kinase inhibitor — completes the RAF/MEK/ERK pathway blockade in combination with BRAF inhibitor.
- Without assistance, Cotellic costs commonly run approximately $11,000–$14,000 per month.
- Through AffordMyPrescriptions, qualifying patients can access Cotellic for a flat $69.95 per month.
- Other BRAF + MEK combinations for BRAF V600-mutated melanoma: Tafinlar (dabrafenib) + Mekinist (trametinib — generic now available), Braftovi (encorafenib) + Mektovi (binimetinib). All three combinations comparable efficacy with slightly different toxicity profiles. For BRAF V600E-mutated NSCLC: dabrafenib + trametinib. For BRAF V600E-mutated CRC: encorafenib + cetuximab (BEACON). For melanoma overall: checkpoint inhibitors (pembrolizumab/Keytruda, nivolumab/Opdivo, ipilimumab/Yervoy, nivolumab + relatlimab/Opdualag, nivolumab + ipilimumab combination) are increasingly preferred first-line; targeted BRAF/MEK reserved for selected scenarios. BRAF testing essential.
What is Cotellic Prescription Assistance Program?
The Cotellic Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Cotellic (used in combination with vemurafenib for BRAF V600-mutated unresectable or metastatic melanoma) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, oncology coordination, BRAF mutation documentation, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing advanced melanoma.
At AffordMyPrescriptions, our Patient Advocates handle the entire Cotellic PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation (typically including BRAF testing results, prior therapy history, and clinical criteria), follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Cotellic MEK inhibitor therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Cotellic enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your BRAF V600-mutated melanoma treatment.
Pharmacy Price Comparison
- Without assistance, Cotellic costs thousands of dollars per month at specialty pharmacies. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this targeted melanoma therapy accessible if you qualify. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Cotellic advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Mektovi (alt MEK) | ~$12,000/mo | Alt MEK with Braftovi |
| Walgreens | ~$13,500/mo | Save substantially |
| CVS Pharmacy | ~$14,000/mo | Save substantially |
| Walmart | ~$11,500/mo | Save substantially |
| Specialty pharmacy | ~$11,000/mo | Save substantially |
| Generic trametinib (Mekinist) | ~$5,000/mo | Generic MEK alt — substantial |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Cotellic — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Cotellic Prescription Program?
The Cotellic Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Generic trametinib (Mekinist) is substantially cheaper MEK inhibitor alternative — used with dabrafenib in equivalent BRAF+MEK combination.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Cotellic assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Cotellic is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Cotellic:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $11,000–$14,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Cotellic assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Cotellic Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Cotellic:
Cotellic is a selective oral MEK1/2 kinase inhibitor designed for combination use with vemurafenib (Zelboraf — BRAF inhibitor) in BRAF V600-mutated melanoma. The combination addresses both BRAF and downstream MEK signaling — overcoming the paradoxical pathway reactivation seen with BRAF inhibitor monotherapy. coBRIM trial established Cotellic + vemurafenib over vemurafenib alone; IMspire150 established the triple combination with atezolizumab.
How It Works:
BRAF V600 mutations (V600E most common, V600K less common) occur in approximately 50% of cutaneous melanomas. Mutant BRAF constitutively activates downstream MEK and ERK kinases driving tumor proliferation, survival, and metastasis. BRAF inhibitor monotherapy initially produces dramatic responses but is followed by adaptive pathway reactivation and resistance within months. Cobimetinib selectively inhibits MEK1/2 kinases — blocking downstream of BRAF and preventing pathway reactivation. Combined with BRAF inhibition (vemurafenib), the dual blockade improves response rates, prolongs PFS and OS, and partly delays resistance vs BRAF monotherapy. Triple combination with checkpoint inhibitor (atezolizumab) further extends benefit per IMspire150 (historical first-line approach).
Form and Use:
Cotellic 20 mg tablets. Recommended dose 60 mg (3 tablets) once daily for 21 days, followed by 7 days off (28-day cycle). Combined with vemurafenib 960 mg twice daily. May add atezolizumab per IMspire150 protocol. Continue until disease progression or unacceptable toxicity. Periodic ECG (QT, LVEF), CBC, comprehensive metabolic panel, eye exams, dermatologic evaluation. Avoid strong CYP3A4 inhibitors (reduce dose) and inducers (avoid).
Generic Availability:
No generic Cotellic. Other BRAF + MEK combinations for BRAF V600-mutated melanoma: dabrafenib (Tafinlar) + trametinib (Mekinist — generic now available — substantially cheaper MEK option in the same therapeutic class), encorafenib (Braftovi) + binimetinib (Mektovi). All three combinations have comparable efficacy with slightly different toxicity profiles (e.g., Tafinlar+Mekinist has higher pyrexia; Braftovi+Mektovi has cleaner side effect profile in some respects; Zelboraf+Cotellic has photosensitivity and arthralgia profile). For BRAF V600E-mutated NSCLC: dabrafenib + trametinib. For BRAF V600E-mutated CRC: encorafenib + cetuximab (BEACON). For melanoma overall: checkpoint inhibitors (Keytruda, Opdivo, Yervoy, Opdualag, Opdivo + Yervoy combinations) are increasingly preferred first-line per Checkpoint trials; targeted BRAF/MEK reserved for selected scenarios (high disease burden, rapidly progressive, or specific clinical contexts). BRAF testing (next-generation sequencing or PCR/IHC) essential. Adjuvant BRAF + MEK or anti-PD-1 indicated after surgery in resected stage III BRAF-mutated melanoma.
Warnings:
Cardiomyopathy with LVEF decline (monitor at baseline, after 1 month, then every 3 months — hold for symptomatic CHF or significant LVEF decline), hemorrhage (including GI, GU, intracranial — serious and sometimes fatal), severe dermatologic reactions including SJS/TEN, retinal pigment epithelial detachment (RPED) and other ocular toxicity (regular ophthalmologic monitoring — vision changes require evaluation), hepatotoxicity (monitor LFTs), rhabdomyolysis (monitor CPK), photosensitivity (with vemurafenib — strict photoprotection), interstitial lung disease (with vemurafenib), embryo-fetal toxicity. Other: diarrhea, nausea, vomiting, rash, fatigue, hypertension, peripheral edema. Combination with atezolizumab adds immune-related adverse events. Drug interactions: strong CYP3A4 inhibitors (azoles, clarithromycin, ritonavir, grapefruit) increase cobimetinib — reduce dose; strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John’s wort) reduce efficacy — avoid.
FAQ (Frequently Asked Questions)
How much does Cotellic cost without insurance?
$11,000–$14,000 per month (Cotellic alone — combined with vemurafenib doubles total monthly cost). Annual combination cost can exceed $250,000–$300,000 without assistance.
Why is BRAF testing required before starting Cotellic?
Cotellic is FDA-approved specifically for BRAF V600-mutated melanoma (V600E or V600K). BRAF testing (typically by NGS or PCR/IHC) identifies appropriate candidates. BRAF V600 mutations occur in approximately 50% of cutaneous melanomas. Patients without BRAF V600 mutations should not receive BRAF + MEK combination therapy — checkpoint inhibitors are appropriate instead.
What is the difference between Cotellic and other MEK inhibitors (Mekinist/trametinib, Mektovi/binimetinib)?
All MEK1/2 inhibitors. Cotellic (cobimetinib) paired with vemurafenib (Zelboraf). Mekinist (trametinib — generic now available, substantially cheaper) paired with dabrafenib (Tafinlar). Mektovi (binimetinib) paired with encorafenib (Braftovi). Comparable efficacy across the three combinations with slightly different toxicity profiles. Choice often driven by clinician familiarity, insurance, and side effect considerations.
Why are MEK inhibitors always combined with BRAF inhibitors?
BRAF inhibitor monotherapy causes paradoxical reactivation of the MAPK pathway and rapid resistance. Adding MEK inhibition prevents pathway reactivation — improves response rates, delays resistance, prolongs PFS and OS, and reduces certain BRAF-monotherapy-specific toxicities (e.g., cutaneous squamous cell carcinoma). All three FDA-approved BRAF inhibitors in melanoma are used in combination with MEK inhibitors.
Should I take BRAF + MEK or immunotherapy first?
For BRAF-mutated melanoma, immunotherapy (anti-PD-1 ± anti-CTLA-4) is increasingly preferred first-line based on durability of responses and DREAMseq trial. BRAF + MEK appropriate for selected scenarios — high disease burden, rapidly progressive disease, brain metastases, or when immunotherapy contraindicated. Discuss sequencing with your melanoma medical oncologist.
Take Control of Your Medication Costs
BRAF + MEK combination targeted therapy for BRAF V600-mutated melanoma should not be derailed by cost. Generic trametinib + Tafinlar offers substantial savings; checkpoint immunotherapy increasingly preferred first-line. Our Cotellic advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Cotellic through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.